{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:51Z","timestamp":1793896491236,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:32:56Z","timestamp":1676064776000},"page":"e222-e231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting"],"prefix":"10.1016","volume":"23","author":[{"given":"Anda","family":"Gershon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esprit","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Montez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-1769","authenticated-orcid":false,"given":"Grace","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Wei-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn M.","family":"Flahavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0001","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.clml.2011.02.003","article-title":"Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry","volume":"11","author":"Juliusson","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.02.002_bib0002","unstructured":"National Cancer Institute. SEER Cancer Statistics Review, 1975-2018. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2018\/. Accessed: September 9, 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood.2021012456","article-title":"A slow-go prognosis for older patients with newly diagnosed AML","volume":"138","author":"Schiller","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0004","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.02.002_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.02.002_bib0007","first-page":"1","article-title":"The changing landscape of treatment in acute myeloid leukemia","volume":"40","author":"Koenig","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2023.02.002_bib0008","unstructured":"Servier Pharmaceuticals. TIBSOVO (ivosidenib) [prescribing information]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211192_s008lbl.pdf. Accessed: September 9, 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0009","unstructured":"Celgene Corporation. IDHIFA (enasidenib) [prescribing information]. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_idhifa.pdf. Accessed September 9, 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0010","unstructured":"Pfizer Inc. DAURISMO (glasdegib) [prescribing information]. Available at: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11336. Accessed: 9 September 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0011","unstructured":"AbbVie Inc. VENCLEXTA (Venetoclax) [prescribing information]. Available at: https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf. Accessed: 9 September 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0012","unstructured":"Food and Drug Administration. FDA approves venetoclax in combination for AML in adults. Available at: https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults. Accessed: September 9, 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2018-99-117179","article-title":"Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy","volume":"132","author":"Pollyea","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0015","unstructured":"Food and Drug Administration. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia. Accessed: September 9, 2022."},{"key":"10.1016\/j.clml.2023.02.002_bib0016","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.02.002_bib0017","unstructured":"National Comprehensive Cancer Network. NCCN guidelines for acute myeloid leukemia. Version 2.2022. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411 Accessed: September 9, 2022. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia V.3.2021. \u00a9 National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.clml.2023.02.002_bib0018","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020","journal-title":"arXiv:2001.09765v1"},{"key":"10.1016\/j.clml.2023.02.002_bib0019","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.clml.2023.02.002_bib0020","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood-2016-09-738765","article-title":"Down for the count in acute myeloid leukemia","volume":"128","author":"Goldberg","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0021","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2016-04-711986","article-title":"MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia","volume":"128","author":"Rauch","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-134832","article-title":"Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0023","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood-2021-147851","article-title":"Real world treatment patterns and outcomes of venetoclax (Ven) and hypomethylating agents (HMA) in patients with newly diagnosed acute myeloid leukemia (AML) in the United States","volume":"138","author":"Vachhani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0024","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1200\/OP.20.00395","article-title":"Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia","volume":"17","author":"Jillella","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2023.02.002_bib0025","doi-asserted-by":"crossref","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","article-title":"Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience","volume":"114","author":"De Bellis","year":"2022","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0026","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2021-151285","article-title":"Comparative effectiveness of venetoclax combinations vs other therapies among patients with newly diagnosed acute myeloid leukemia: results from the AML Real World Evidence (ARC) initiative","volume":"138","author":"Garcia","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134830","article-title":"Treatment patterns and outcomes of patients with newly diagnosed acute myeloid leukemia (AML) treated with hypomethylating agents (HMA) in the United States (US)","volume":"126","author":"Pardee","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0028","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.02.002_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood-2021-151586","article-title":"Real-world management of patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens: results from the AML Real World Evidence (ARC) initiative","volume":"138","author":"Vachhani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.002_bib0031","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncologist"},{"issue":"suppl","key":"10.1016\/j.clml.2023.02.002_bib0032","first-page":"S98","volume":"26","author":"Tomlinson","year":"2020","journal-title":"ASTCT"},{"key":"10.1016\/j.clml.2023.02.002_bib0033","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/13696998.2018.1425209","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations","volume":"21","author":"Stein","year":"2018","journal-title":"J Med Econ"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.02.002_bib0034","doi-asserted-by":"crossref","first-page":"e19513","DOI":"10.1200\/JCO.2020.38.15_suppl.e19513","article-title":"Treatment outcomes and healthcare resource utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting","volume":"38","author":"Lyons","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 29","key":"10.1016\/j.clml.2023.02.002_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2020.38.29_suppl.72","article-title":"Healthcare resource utilization and total cost of care in older patients with acute myeloid leukemia ineligible for intensive chemotherapy","volume":"38","author":"LeBlanc","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502300037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502300037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:06Z","timestamp":1761871326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502300037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S215226502300037X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}